0001104659-24-040642.txt : 20240328 0001104659-24-040642.hdr.sgml : 20240328 20240328175727 ACCESSION NUMBER: 0001104659-24-040642 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240328 FILED AS OF DATE: 20240328 DATE AS OF CHANGE: 20240328 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gilad Oren CENTRAL INDEX KEY: 0001929300 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39069 FILM NUMBER: 24800944 MAIL ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aprea Therapeutics, Inc. CENTRAL INDEX KEY: 0001781983 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3805 OLD EASTON ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18902 BUSINESS PHONE: 617-463-9385 MAIL ADDRESS: STREET 1: 3805 OLD EASTON ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18902 4 1 tm2410009-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-03-28 0 0001781983 Aprea Therapeutics, Inc. APRE 0001929300 Gilad Oren 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 1 1 0 0 President, CEO 0 Common Stock 2024-03-28 4 A 0 6725 0.00 A 331495 D Common Stock 1200 I By daughter Common Stock 600 I By son Stock Options (Right to Buy) 6.69 2024-03-28 4 A 0 26900 0.00 A 2024-03-28 Common Stock 26900 26900 D These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock ("Common Stock") in three (3) equal annual installments beginning on March 28, 2025, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Twenty-five percent of these options vest on March 28, 2025, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. /s/ John Hamill, Attorney-in-Fact 2024-03-28